Microvascular angina Vasospastic angina
Conditions
Interventions
Aspirin 486 mg
L-NMMA acetate 8 micromol/min for 5 minutes
bradykinin acetate 25 ng/min, 50 ng/min and 100 ng/min for 2 minutes each, 3 times
nitroglycerin 0.3 mg sublingual administration. Four times measurement of FMD and RH-PAT.
Sponsors
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ?Patients who are hospitalized for being suspected microvascular and/or coronary vasospastic angina by catheterization, or our outpatients diagnosed with microvascular and/or coronary vasospastic angina. ?Regardless of gender.
Exclusion criteria
Exclusion criteria: ?Patients in hospital due to acute coronary syndrome. ?Patients with cardiogenic shock or heart failure. ?Patients with end-stage renal failure with internal shunt. ?Patients taking continuous intravenous infusion of cardiovascular agents such as inotropes and vasodilators. ?Patients who have resting systolic blood pressure below 100 mmHg or more than 200mmHg at the time of measurement of endothelial functions. ?Patients who have arrhythmia such as atrial fibrillation and are considered to be difficult to measure vascular endothelial function. ?Patients with a history of aspirin asthma. ?Patients who are taking any antithrombotic therapies except single antiplatelet agent. ?Patients who are pregnant or have a possibility of pregnancy, and who are falling within 28 days after childbirth or breast-feeding ?Patients are considered to be difficult to participate in the trial due to mental illness or psychiatric symptoms. ?Patients who are judged to be inappropriate for participating in the study by us.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endothelial functions as evaluated by FMD (flow-mediated dilation) and RH-PAT (reactive hyperemia-peripheral arterial tonometry). | — |
Secondary
| Measure | Time frame |
|---|---|
| Endothelial function-related biomarkers such as NOx, adiponectin, Rho-kinase activity, ADMA (asymmetric dimethylarginine). | — |
Countries
Japan
Contacts
Public ContactShoko Kajitani
Tohoku University Graduate School of Medicine Cardiovascular Medicine
Outcome results
None listed